“We have to invest time in getting to know the team to prevent discrepancies that can affect the company”
Esther Riambau
She holds degrees in Biology and Biochemistry and a Master in Business Administration (MBA). She is the co-founder and CEO of Oniria Therapeutics, and co-founder and board member of Gate2Brain. Her slogan? “My training in is technology transfer but my heart is in startups.”
In late March, the Vall d’Hebron Institute of Oncology (VHIO), University of Barcelona (UB) and ICREA kicked off Oniria Therapeutics to eliminate persistent tumor cells. Specifically, the new spinoff, which has received financial support from the ”la Caixa” Foundation, Asociación Española Contra el Cáncer and Carlos III Health Institute (ISCIII), focuses on developing therapies to eliminate persistent tumor cells that are resistant to conventional treatments and can lead to relapses and affect the progression of patients in the more advanced stages of the disease.
We spoke with Esther Riambau, CEO of the project, who explained her history as an entrepreneur, how she joined the project, the importance of knowing the team well, and the challenges Oniria Therapeutics is facing in the immediate future. The spin-off is seeking funding to scale the project.
More stories
All stories
